Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
78%(7 trials)

Phase Distribution

Ph phase_1
4
44%
Ph phase_2
2
22%
Ph phase_3
3
33%

Phase Distribution

4

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (44.4%)
Phase 22 (22.2%)
Phase 33 (33.3%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_3

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

NCT00603642
completedphase_3

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy

NCT00102336
completedphase_3

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

NCT00102323
completedphase_1

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

NCT00299182
completedphase_2

Open Label Extension Study of AMG 531 in Japanese Subjects With ITP

NCT00440037
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00603642Phase 3

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Completed
NCT00102336Phase 3

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy

Completed
NCT00102323Phase 3

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

Completed
NCT00299182Phase 1

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Completed
NCT00440037Phase 2

Open Label Extension Study of AMG 531 in Japanese Subjects With ITP

Completed
NCT00515203Phase 1

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Completed
NCT00147225Phase 1

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

Completed
NCT00283439Phase 1

A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma

Completed
NCT00418665Phase 2

A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9